Comparative Pharmacology
Head-to-head clinical analysis: AMMONIA N 13 versus CARDIOGEN 82.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIA N 13 versus CARDIOGEN 82.
AMMONIA N 13 vs CARDIOGEN-82
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
CardioGen-82 (rubidium Rb-82 generator) produces rubidium Rb-82, a positron-emitting radiotracer that is taken up by myocardial cells via the sodium-potassium ATPase pump, reflecting myocardial perfusion. Its distribution is proportional to blood flow, allowing PET imaging of myocardial perfusion defects.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
Single intravenous dose of 0.3-0.6 mCi (11.1-22.2 MBq) followed by a 0.9% sodium chloride flush at 1-3 mL/sec.
None Documented
None Documented
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
Terminal elimination half-life is 60–90 seconds (for the parent radionuclide Rb-82). Clinical context: Short half-life allows rapid repeat imaging; myocardial uptake is proportional to blood flow.
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Renal; >90% eliminated unchanged in urine within 24 hours. Fecal excretion is negligible.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical